Table 1.
Relevant clinical and laboratory features
| All, N=256 | Central, N=124 (48.4%) | Peripheral, N=132 (51.6%) | P-value | |
|---|---|---|---|---|
|
| ||||
| Age, years (range) | 58 (32–77) | 55 (32–77) | 60 (37–77) | 0.001 |
| Gender | 0.28 | |||
| Male | 108 (42.2%) | 48 (38.7%) | 60 (45.5%) | |
| Female | 148 (57.8%) | 76 (61.3%) | 72 (54.5%) | |
| KPS | 90 (60–100) | 90 (70–95) | 90 (60–100) | 0.002 |
| Smoking status | ||||
| Never | 179 (69.9%) | 92 (74.2%) | 87 (65.9%) | 0.15 |
| Ever | 77 (30.1%) | 32 (25.8%) | 45 (34.1%) | |
| Cigarette index | 600 (200–2000) | 600 (400–1200) | 600 (200–2000) | 0.69 |
| Clinical stage | <0.001 | |||
| I | 40 (15.6%) | 8 (6.5%) | 32 (24.2%) | |
| II | 7 (2.7%) | 6 (4.8%) | 1 (0.8%) | |
| IIIA | 56 (21.9%) | 24 (19.3%) | 32 (24.2%) | |
| IIIB + IIIC | 15 (5.9%) | 10 (8.1%) | 5 (3.8%) | |
| IV | 138 (53.9%) | 76 (61.3%) | 62 (47.0%) | |
| Distal metastasis | ||||
| Brain | 53 (20.7%) | 31 (39.1%) | 22 (16.7%) | 0.10 |
| Bone | 68 (26.6%) | 44 (35.5%) | 24 (18.2%) | 0.002 |
| Liver | 28 (10.9%) | 16 (12.9%) | 12 (9.1%) | 0.33 |
| Others | 36 (14.1%) | 16 (12.9%) | 20 (15.2%) | 0.61 |
| EGFR status | ||||
| Wild-type | 124 (48.4%) | 68 (54.8%) | 56 (42.4%) | 0.06 |
| Mutant-type | 132 (51.6%) | 56 (45.2%) | 76 (57.6%) | |
| 21 L858R | 75 (56.8%) | 28 (50.0%) | 47 (61.9%) | 0.14 |
| 19 del | 52 (39.4%) | 24 (42.9%) | 28 (36.8%) | |
| Others | 5 (3.8%) | 4 (7.1%) | 1 (1.3%) | |
| CEA (ng/mL), n=243 | 6.70 (0.50–709.30) | 8.11 (0.50–595.20) | 5.12 (0.89–709.30) | 0.07 |
| LDH (U/L), n=243 | 188 (107–1996) | 191 (107–1996) | 186 (111–477) | 0.07 |
| LMR, n=254 | 3.15 (0.77–13.71) | 2.97 (1.31–13.71) | 3.64 (0.77–8.58) | 0.006 |
| Contralateral pulmonary metastasis | 0.001 | |||
| No | 185 (72.3%) | 78 (62.9%) | 107 (81.1%) | |
| Yes | 71 (27.7%) | 46 (37.1%) | 25 (18.9%) | |
| Visceral pleural nodule | 0.71 | |||
| No | 158 (61.7%) | 78 (62.9%) | 80 (60.6%) | |
| Yes | 98 (38.3%) | 46 (37.1%) | 52 (39.4%) | |
| Interlobar pleural nodule | 0.10 | |||
| No | 201 (78.5%) | 92 (74.2%) | 109 (82.6%) | |
| Yes | 55 (21.5%) | 32 (25.8%) | 23 (17.4%) | |
| Pleural effusion | <0.001 | |||
| No | 187 (73.0%) | 69 (55.6%) | 118 (89.4%) | |
| Yes | 69 (27.0%) | 55 (44.4%) | 14 (10.6%) | |
| COPD | 0.53 | |||
| No | 228 (89.1%) | 112 (90.3%) | 116 (87.9%) | |
| Yes | 28 (10.9%) | 12 (9.7%) | 16 (12.1%) | |
| ILD | 0.76 | |||
| No | 188 (73.4%) | 90 (72.6%) | 98 (74.2%) | |
| Yes | 68 (26.6%) | 34 (27.4%) | 34 (25.8%) | |
Abbreviations: CEA, carcino-embryonic antigen; ILD, interstitial lung disease; LDH, lactate dehydrogenase; LMR, lymphocyte–monocyte ratio; KPS, Karnofsky Performance Status.